Incannex Healthcare (NASDAQ:IXHL – Get Free Report) and Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.
Earnings and Valuation
This table compares Incannex Healthcare and Arbutus Biopharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Incannex Healthcare | $10,000.00 | 3,046.25 | -$18.46 million | ($1.39) | -1.24 |
| Arbutus Biopharma | $18.14 million | 34.58 | -$72.85 million | ($0.43) | -7.70 |
Incannex Healthcare has higher earnings, but lower revenue than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Incannex Healthcare | 0 | 0 | 0 | 0 | 0.00 |
| Arbutus Biopharma | 0 | 0 | 4 | 0 | 3.00 |
Arbutus Biopharma has a consensus price target of $5.50, indicating a potential upside of 66.16%. Given Arbutus Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Arbutus Biopharma is more favorable than Incannex Healthcare.
Profitability
This table compares Incannex Healthcare and Arbutus Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Incannex Healthcare | N/A | -182.23% | -127.38% |
| Arbutus Biopharma | -1,137.65% | -68.18% | -51.55% |
Risk and Volatility
Incannex Healthcare has a beta of 7.44, suggesting that its stock price is 644% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500.
Insider & Institutional Ownership
0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 26.5% of Incannex Healthcare shares are owned by insiders. Comparatively, 4.0% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Arbutus Biopharma beats Incannex Healthcare on 8 of the 14 factors compared between the two stocks.
About Incannex Healthcare
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
